In addition to vemurafenib, there are other BRAF inhibitors that can be used in BRAF‐mutant LCH such as dabrafenib and other MAPK inhibitors such as trametinib and cometinib that are broader spectrum and can be used in LCH with alterations in other parts of the MAPK pathway, even those involving more downstream signaling molecules. Here, BRAF is linked to Langerhans cell histiocytosis.